Fresenius SE: Berenberg raises target price
(CercleFinance.com) - Broker Berenberg, which has a buy rating on the Fresenius share, says that it has raised its corresponding target price for the German healthcare group to 74.
8 euros (vs. 70.95 euros previously).
In a note sent to its clients, the broker explains that it expects an improvement in the American performance of Kabi, its perfusion, transfusion and clinical nutrition business.
Berenberg also expects better visibility on the profit margins of the group's hospital care business in Germany.
Its new target price for the share gives it upside potential of 74%.
The share is pretty flat today.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
8 euros (vs. 70.95 euros previously).
In a note sent to its clients, the broker explains that it expects an improvement in the American performance of Kabi, its perfusion, transfusion and clinical nutrition business.
Berenberg also expects better visibility on the profit margins of the group's hospital care business in Germany.
Its new target price for the share gives it upside potential of 74%.
The share is pretty flat today.
Copyright (c) 2019 CercleFinance.com. All rights reserved.